<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Quinapril</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00881</strong>&#160; (APRD00523)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Quinapril is a prodrug that belongs to the angiotensin-converting enzyme (<span class="caps">ACE</span>) inhibitor class of medications. It is metabolized to quinaprilat (quinapril diacid) following oral administration. Quinaprilat is a competitive inhibitor of <span class="caps">ACE</span>, the enzyme responsible for the conversion of angiotensin I (<span class="caps">ATI</span>) to angiotensin II (<span class="caps">ATII</span>). <span class="caps">ATII</span> regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (<span class="caps">RAAS</span>). Quinapril may be used to treat essential hypertension and congestive heart failure.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00881/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00881/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00881.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00881.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00881.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00881.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00881.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00881">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Quinaprilum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Quinapril Hydrochloride</strong>
          <div class="cas">82586-55-8</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000465/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000465/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: IBBLRJGOOANPTQ-JKVLGAQCSA-N</li>
              <li>Monoisotopic Mass: 474.192149819</li>
              <li>Average Mass: 474.977</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000465">DBSALT000465</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Accupril</td><td>Pfizer</td></tr><tr><td>Accuprin</td><td>Pfizer (Italy)</td></tr><tr><td>Accupro</td><td>Pfizer (Austria, Denmark, Finland, Germany, Hungary, Ireland, Sweden, Switzerland, United Kingdom, Ukraine), Godecke (Czech Republic, Germany, Poland, Russia), Parke, Davis (Germany)</td></tr><tr><td>Acequin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Acuitel</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Korec</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Quinazil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Accupro Comp</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Accuretic</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Accuzide</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Acequide</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Acuilix</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Bicetil</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Co-Quinapril</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Koretic</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Lidaltrin Diu</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Quimea</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>QuinaLich comp</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Quinaplus</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Quinapril comp</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Quinaretic</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Quinazide</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Quiril Comp</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr><tr><td>Stadapress</td><td>quinapril hydrochloride + hydrochlorothiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/angiotensin-converting-enzyme-inhibitors">Angiotensin-Converting Enzyme Inhibitors</a></li>
<li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>85441-61-8</td></tr><tr><th>Weight</th><td>Average: 438.5161<br>Monoisotopic: 438.21547208</td></tr><tr><th>Chemical Formula</th><td>C<sub>25</sub>H<sub>30</sub>N<sub>2</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>JSDRRTOADPPCHY-HSQYWUDLSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(3S)-2-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CC2=CC=CC=C2C[C@H]1C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids and Derivatives</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td>Alpha Amino Acid Esters; Alpha Amino Acid Amides; Isoquinolines and Derivatives; Phenylpropylamines; Fatty Acid Esters; Dicarboxylic Acids and Derivatives; Tertiary Carboxylic Acid Amides; Tertiary Amines; Carboxylic Acid Esters; Carboxylic Acids; Dialkylamines; Polyamines; Enolates; Ethers</td></tr><tr><th>Substituents</th><td>alpha-amino acid ester; alpha-amino acid amide; alpha-amino acid or derivative; isoquinoline; phenylpropylamine; fatty acid ester; benzene; dicarboxylic acid derivative; tertiary carboxylic acid amide; carboxamide group; tertiary amine; carboxylic acid ester; secondary aliphatic amine; secondary amine; polyamine; ether; enolate; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of hypertension and as adjunct therapy in the treatment of congestive heart failure. May also be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. </td></tr><tr><th>Pharmacodynamics</th><td>Quinapril is a nonpeptide, non-sulfhydryl prodrug that is deesterified to quinaprilat (quinapril diacid), its major active metabolite following oral administration. Quinaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of quinaprilat by causing increased vasodilation and decreased blood pressure.</td></tr><tr><th>Mechanism of action</th><td>There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Quinaprilat, the principle active metabolite of quinapril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Quinaprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors. </td></tr><tr><th>Absorption</th><td>Peak plasma concentrations of quinapril occur within one hour following oral administration. The extent of absorption is at least 60%. The rate and extent of quinapril absorption are diminished moderately (approximately 25-30%) when ACCUPRIL tablets are administered during a high-fat meal.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>97%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Quinapril</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01141">Quinaprilat</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1263">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose</td></tr><tr><th>Half life</th><td>Elimination half life is 2 hours with a prolonged terminal phase of 25 hours. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Overdose may lead to severe hypotension. LD<sub>50</sub>=1739mg/kg (orally in mice). The most common adverse effects observed in controlled clinical trials were dizziness, cough, chest pain, dyspnea, fatigue, and nausea/vomiting. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Quinapril Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00153?highlight%5Bcompounds%5D%5B%5D=DB00881&amp;highlight%5Bproteins%5D%5B%5D=DB00881">SMP00153</a></td></tr><tr><td>Quinapril Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00596?highlight%5Bcompounds%5D%5B%5D=DB00881&amp;highlight%5Bproteins%5D%5B%5D=DB00881">SMP00596</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.5597</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9409</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8208</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8895</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7344</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5869</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8258</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8594</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8412</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5356</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8597</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6832</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8636</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6016</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5347</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5162</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9091
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9294
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9596
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2690 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9763
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7176
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer pharmaceuticals ltd</li>
<li>Actavis totowa llc</li>
<li>Apotex inc</li>
<li>Genpharm inc</li>
<li>Invagen pharmaceuticals inc</li>
<li>Lupin ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Sandoz inc</li>
<li>Sun pharmaceutical industries ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc florida</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li>Eon Labs</li>
<li>Goedecke GmbH</li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.invagen.com">InvaGen Pharmaceuticals Inc.</a></li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>20 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>40 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>5 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Accupril 10 mg tablet</td><td>2.02USD</td><td>tablet</td></tr><tr><td>Accupril 20 mg tablet</td><td>2.02USD</td><td>tablet</td></tr><tr><td>Accupril 40 mg tablet</td><td>2.02USD</td><td>tablet</td></tr><tr><td>Accupril 5 mg tablet</td><td>2.02USD</td><td>tablet</td></tr><tr><td>Quinapril 10 mg tablet</td><td>1.57USD</td><td>tablet</td></tr><tr><td>Quinapril 20 mg tablet</td><td>1.57USD</td><td>tablet</td></tr><tr><td>Quinapril 40 mg tablet</td><td>1.57USD</td><td>tablet</td></tr><tr><td>Quinapril 5 mg tablet</td><td>1.57USD</td><td>tablet</td></tr><tr><td>Quinapril HCl 10 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Quinapril HCl 20 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Quinapril HCl 40 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Quinapril HCl 5 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Quinaretic 10-12.5 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Quinaretic 20-12.5 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Quinaretic 20-25 mg tablet</td><td>1.27USD</td><td>tablet</td></tr><tr><td>Accupril 10 mg Tablet</td><td>0.96USD</td><td>tablet</td></tr><tr><td>Accupril 20 mg Tablet</td><td>0.96USD</td><td>tablet</td></tr><tr><td>Accupril 40 mg Tablet</td><td>0.96USD</td><td>tablet</td></tr><tr><td>Accupril 5 mg Tablet</td><td>0.96USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5684016</td><td>1995-05-04</td><td>2015-05-04</td></tr><tr><td>Canada</td><td>2023089</td><td>2003-01-14</td><td>2010-08-10</td></tr><tr><td>Canada</td><td>1331615</td><td>1994-08-23</td><td>2011-08-23</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>120-130 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>1 mg/L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>3.2</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>8.50e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.39</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.96</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>3.7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>5.2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>95.94</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>10</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>119.96</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>47.36</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Om P. Goel, Uldis Krolls, &#8220;Crystalline quinapril and a process for producing the same.&#8221; U.S. Patent US4761479, issued August, 1982.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4761479&amp;tbm=pts" target="_blank">US4761479 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an <span class="caps">ACE</span> inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care. 2004 Jul;27(7):1712-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15220251">Pubmed</a></li>
	<li>Kieback AG, Felix SB, Reffelmann T: Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1337-47. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19761414">Pubmed</a></li>
	<li>Pitt B, O&#8217;Neill B, Feldman R, Ferrari R, Schwartz L, Mudra H, Bass T, Pepine C, Texter M, Haber H, Uprichard A, Cashin-Hemphill L, Lees RS: The QUinapril Ischemic Event Trial (<span class="caps">QUIET</span>): evaluation of chronic <span class="caps">ACE</span> inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol. 2001 May 1;87(9):1058-63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11348602">Pubmed</a></li>
	<li>Tsikouris JP, Suarez JA, Meyerrose GE, Ziska M, Fike D, Smith J: Questioning a class effect: does <span class="caps">ACE</span> inhibitor tissue penetration influence the degree of fibrinolytic balance alteration following an acute myocardial infarction? J Clin Pharmacol. 2004 Feb;44(2):150-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14747423">Pubmed</a></li>
	<li>Valles Prats M, Matas Serra M, Bronsoms Artero J, Mate Benito G, Torguet Escuder P, Mauri Nicolas JM: Quinapril <span class="caps">ACE</span>-inhibition effects on adrenergic parameters in moderate essential hypertension. Kidney Int Suppl. 1996 Jun;55:S104-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8743525">Pubmed</a></li>
	<li>Voors AA, van Geel PP, Oosterga M, Buikema H, van Veldhuisen DJ, van Gilst WH: Vascular effects of quinapril completely depend on <span class="caps">ACE</span> insertion/deletion polymorphism. J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):130-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15526248">Pubmed</a></li>
	<li>Yamada S, Muraoka I, Kato K, Hiromi Y, Takasu R, Seno H, Kawahara H, Nabeshima T: Elimination kinetics of quinaprilat and perindoprilat in hypertensive patients with renal failure on haemodialysis. Biol Pharm Bull. 2003 Jun;26(6):872-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12808303">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D03752" target="_blank">D03752 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07398" target="_blank">C07398 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54892" target="_blank">54892 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506309" target="_blank">46506309 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.49565.html" target="_blank">49565 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=8713" target="_blank">8713 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1592" target="_blank">CHEMBL1592 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000588" target="_blank">DAP000588 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451205" target="_blank">PA451205 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=1947672" target="_blank">1947672 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/quinap.htm" target="_blank">http://www.rxlist.com/cgi/generic/quinap.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/quinapril.html" target="_blank">http://www.drugs.com/cdi/quinapril.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=Acc1002.html&amp;contentName=Accupril&amp;contentId=03" target="_blank">http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=Acc1002.html&amp;contentName=Accupril&amp;contentId=03 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Quinapril" target="_blank">Quinapril <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C09AA06<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C09#C09">C09 &#8212; AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</a></li><li><a href="/atc/C09A#C09A">C09A &#8212; ACE INHIBITORS, PLAIN</a></li><li><a href="/atc/C09AA#C09AA">C09AA &#8212; ACE inhibitors, plain</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:32.04</li></ul></td></tr><tr><th>PDB Entries</th><td><ul><li><a class="wishart-link-out" href="http://www.rcsb.org/pdb/explore.do?structureId=1UZF" target="_blank">1UZF <span class="glyphicon glyphicon-new-window"> </span></a></li></ul></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00594">Amiloride</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB06196">Icatibant</a></td><td>Icatibant may attenuate the antihypertensive effect of ACE inhibitors by pharmacodynamic antagonism. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The ACE inhibitor increases serum levels of lithium</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Quinapril may decrease the absorption of tetracycline.</td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Tizanidine increases the risk of hypotension with the ACE inhibitor</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00685">Trovafloxacin</a></td><td>Quinapril may decrease the absorption of orally administered Trovafloxacin. The Quinapril formulation contains magnesium ions that may intefere with Trovafloxacin absorption. Administer Trovafloxacin 2 hours before or 6 hours after the Quinapril dose to minimize the interaction. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Do not take with a high-fat meal.</li>
<li>Herbs that may attenuate the antihypertensive effect of quinapril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice. </li>
<li>High salt intake may attenuate the antihypertensive effect of quinapril.</li>
<li>Quinapril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia. </li></ul></td></tr></tbody></table>